Online inquiry

IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8651MR)

This product GTTS-WQ8651MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM), AL amyloidosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8651MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6463MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CT-P23
GTTS-WQ8566MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ6820MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ14512MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SA-237
GTTS-WQ570MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 62-71-3
GTTS-WQ11909MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MLN-1202
GTTS-WQ7377MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ572MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 62-71-3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW